Director at Abbott Laboratories (NYSE: ABT) receives 2,286-share stock grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Babineaux-Fontenot Claire reported acquisition or exercise transactions in this Form 4 filing.

ABBOTT LABORATORIES director Claire Babineaux-Fontenot received a grant of 2,286 common shares on April 24, 2026, recorded at a price of $0.00 per share, as a stock-based award. Following this grant, she directly holds 7,603 Abbott common shares.

The award is structured as restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program. According to the terms, the units will be settled on a one-for-one basis in Abbott common shares upon the earlier of her separation from service, death, or a change in control as defined in the program.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Babineaux-Fontenot Claire

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common shares without par value	2,286	$0.00	--

Holdings After Transaction: Common shares without par value — 7,603 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares granted: 2,286 shares Price per share: $0.00 per share Total shares after grant: 7,603 shares

3 metrics

Shares granted 2,286 shares Restricted stock unit award on April 24, 2026

Price per share $0.00 per share Recorded grant price for the stock award

Total shares after grant 7,603 shares Direct holdings following the reported transaction

Key Terms

restricted stock unit, Incentive Stock Program, change in control

3 terms

restricted stock unit financial

"Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Incentive Stock Program financial

"granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program")"

change in control financial

"death, or the occurrence of a change in control (as defined in the Program)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Form 4 Insider Transactions: What Each Field Means →

04/28/2026 - 06:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Babineaux-Fontenot Claire

(Last)

(First)

(Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK

ILLINOIS

60064

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common shares without par value	04/24/2026		A		2,286⁽¹⁾	A	$0	7,603	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

	/s/ Claire Babineaux-Fontenot by Jessica H. Paik, Attorney-in-Fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Abbott Laboratories (ABT) disclose about Claire Babineaux-Fontenot in this Form 4?

Abbott Laboratories reported that director Claire Babineaux-Fontenot received a grant of 2,286 common shares as a restricted stock unit award. After this grant, she directly holds 7,603 Abbott common shares, reflecting her updated equity position as a board member.

How many Abbott (ABT) shares were granted to Claire Babineaux-Fontenot and at what price?

Claire Babineaux-Fontenot was granted 2,286 Abbott common shares at a recorded price of $0.00 per share. This indicates a compensation-related stock award rather than an open-market purchase, aligning with typical director equity incentive practices at large public companies.

What is the total Abbott (ABT) shareholding of Claire Babineaux-Fontenot after this award?

Following the 2,286-share grant, Claire Babineaux-Fontenot directly holds 7,603 Abbott common shares. This total reflects only her direct ownership reported in the filing and shows the equity stake she now has as a member of Abbott’s board of directors.

How will the restricted stock unit award for Abbott (ABT) director Claire Babineaux-Fontenot be settled?

The restricted stock unit award will be settled one-for-one in Abbott common shares. Settlement occurs on the earlier of her separation from service, death, or a change in control, all as defined in the Abbott Laboratories 2026 Incentive Stock Program governing the award.

Is Claire Babineaux-Fontenot’s Abbott (ABT) Form 4 transaction a market purchase or sale?

The Form 4 shows a grant-type acquisition, not a market trade. The 2,286 shares were awarded at $0.00 per share as a restricted stock unit grant under Abbott’s 2026 Incentive Stock Program, representing compensation rather than an open-market buy or sell transaction.